Skip to main content
Journal cover image

Role of Continuous Glucose Monitoring in Clinical Trials: Recommendations on Reporting.

Publication ,  Journal Article
Schnell, O; Barnard, K; Bergenstal, R; Bosi, E; Garg, S; Guerci, B; Haak, T; Hirsch, IB; Ji, L; Joshi, SR; Kamp, M; Laffel, L; Mathieu, C ...
Published in: Diabetes technology & therapeutics
July 2017

Thanks to significant improvements in the precision, accuracy, and usability of continuous glucose monitoring (CGM), its relevance in both ambulatory diabetes care and clinical research is increasing. In this study, we address the latter perspective and derive provisional reporting recommendations. CGM systems have been available since around the year 2000 and used primarily in people with type 1 diabetes. In contrast to self-measured glucose, CGM can provide continuous real-time measurement of glucose levels, alerts for hypoglycemia and hyperglycemia, and a detailed assessment of glycemic variability. Through a broad spectrum of derived glucose data, CGM should be a useful tool for clinical evaluation of new glucose-lowering medications and strategies. It is the only technology that can measure hyperglycemic and hypoglycemic exposure in ambulatory care, or provide data for comprehensive assessment of glucose variability. Other advantages of current CGM systems include the opportunity for improved self-management of glycemic control, with particular relevance to those at higher risk of or from hypoglycemia. We therefore summarize the current status and limitations of CGM from the perspective of clinical trials and derive suggested recommendations for how these should facilitate optimal CGM use and reporting of data in clinical research.

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Diabetes technology & therapeutics

DOI

EISSN

1557-8593

ISSN

1520-9156

Publication Date

July 2017

Volume

19

Issue

7

Start / End Page

391 / 399

Related Subject Headings

  • Humans
  • Endocrinology & Metabolism
  • Diabetes Mellitus, Type 1
  • Clinical Trials as Topic
  • Blood Glucose Self-Monitoring
  • Blood Glucose
  • 3202 Clinical sciences
  • 1116 Medical Physiology
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Schnell, O., Barnard, K., Bergenstal, R., Bosi, E., Garg, S., Guerci, B., … Home, P. (2017). Role of Continuous Glucose Monitoring in Clinical Trials: Recommendations on Reporting. Diabetes Technology & Therapeutics, 19(7), 391–399. https://doi.org/10.1089/dia.2017.0054
Schnell, Oliver, Katharine Barnard, Richard Bergenstal, Emanuele Bosi, Satish Garg, Bruno Guerci, Thomas Haak, et al. “Role of Continuous Glucose Monitoring in Clinical Trials: Recommendations on Reporting.Diabetes Technology & Therapeutics 19, no. 7 (July 2017): 391–99. https://doi.org/10.1089/dia.2017.0054.
Schnell O, Barnard K, Bergenstal R, Bosi E, Garg S, Guerci B, et al. Role of Continuous Glucose Monitoring in Clinical Trials: Recommendations on Reporting. Diabetes technology & therapeutics. 2017 Jul;19(7):391–9.
Schnell, Oliver, et al. “Role of Continuous Glucose Monitoring in Clinical Trials: Recommendations on Reporting.Diabetes Technology & Therapeutics, vol. 19, no. 7, July 2017, pp. 391–99. Epmc, doi:10.1089/dia.2017.0054.
Schnell O, Barnard K, Bergenstal R, Bosi E, Garg S, Guerci B, Haak T, Hirsch IB, Ji L, Joshi SR, Kamp M, Laffel L, Mathieu C, Polonsky WH, Snoek F, Home P. Role of Continuous Glucose Monitoring in Clinical Trials: Recommendations on Reporting. Diabetes technology & therapeutics. 2017 Jul;19(7):391–399.
Journal cover image

Published In

Diabetes technology & therapeutics

DOI

EISSN

1557-8593

ISSN

1520-9156

Publication Date

July 2017

Volume

19

Issue

7

Start / End Page

391 / 399

Related Subject Headings

  • Humans
  • Endocrinology & Metabolism
  • Diabetes Mellitus, Type 1
  • Clinical Trials as Topic
  • Blood Glucose Self-Monitoring
  • Blood Glucose
  • 3202 Clinical sciences
  • 1116 Medical Physiology
  • 1103 Clinical Sciences